HSBC analysts predict Moderna's RSV vaccine may be priced lo...

HSBC analysts predict Moderna's RSV vaccine may be priced lower than competitors due to potential for more frequent dosing. The upcoming CDC's Advisory Committee meeting on RSV vaccine data could influence Moderna's stock.